Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Non-Current Assets (2017 - 2025)

Serina Therapeutics' Other Non-Current Assets history spans 9 years, with the latest figure at $24000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 52.0% year-over-year to $24000.0; the TTM value through Sep 2025 reached $24000.0, down 52.0%, while the annual FY2022 figure was $50000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $24000.0 at Serina Therapeutics, down from $50000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $50000.0 in Q1 2021 and bottomed at $24000.0 in Q3 2025.
  • The 5-year median for Other Non-Current Assets is $50000.0 (2021), against an average of $48142.9.
  • The largest YoY upside for Other Non-Current Assets was 0.0% in 2021 against a maximum downside of 54.95% in 2021.
  • A 5-year view of Other Non-Current Assets shows it stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then changed by 0.0% to $50000.0 in 2023, then changed by 0.0% to $50000.0 in 2024, then tumbled by 52.0% to $24000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Other Non-Current Assets are $24000.0 (Q3 2025), $50000.0 (Q3 2024), and $50000.0 (Q2 2024).